导管接触性溶栓与AngioJet药物机械导管接触性溶栓治疗急性髂股深静脉血栓的结局比较
这项4年回顾性病例对照研究纳入95例症状≤7天的急性髂股深静脉血栓患者,比较单纯导管接触性溶栓(CDT)与药物机械溶栓联合CDT(PCDT+CDT)。PCDT+CDT组导管留置时间、尿激酶用量、住院时间更短或更少,24小时消肿率更高,随访PTS及中重度PTS发生率更低。
要点
- PCDT+CDT组导管留置时间19.42±4.04小时,短于单纯CDT组60.64±12.04小时(P<.001)。
- PCDT+CDT组尿激酶用量1.80±0.64百万单位,少于单纯CDT组5.82±0.81百万单位(P<.001)。
- PCDT+CDT组PTS发生率27.7%,低于单纯CDT组47.0%(P=.037)。
核心结论
- 在症状持续时间≤7天的髂股深静脉血栓亚组中,与单纯CDT相比,PCDT+CDT可显著缓解早期腿部症状、缩短住院时间、减少出血并发症、促进长期静脉通畅,并降低PTS及中重度PTS的发生比例。
- 短期和长期结局均支持PCDT+CDT在该亚组中优于单纯CDT。
研究设计与样本
- 4年回顾性病例对照研究,连续纳入95例症状持续时间≤7天、累及髂和/或股总静脉的急性症状性髂股深静脉血栓患者。
- 按临床指征分为PCDT+CDT组(44例)与单纯CDT组(51例),比较两组临床特征与结局。
- 治疗后随访3至36个月,采用Kaplan-Meier生存法分析PTS及中重度PTS的比例。
主要发现
- 导管留置时间:PCDT+CDT组19.42±4.04小时 vs 单纯CDT组60.64±12.04小时(P<.001)。
- 尿激酶用量:PCDT+CDT组1.80±0.64百万单位 vs 单纯CDT组5.82±0.81百万单位(P<.001)。
- 术后24小时消肿率:PCDT+CDT组76.79%±7.98% vs 单纯CDT组48.46%±8.62%(P=.026)。
- D-二聚体每日下降速度:PCDT+CDT组3842.34±2048.02 μg/L/D vs 单纯CDT组2266.28±1358.26 μg/L/D(P=.018)。
- 总住院时间:PCDT+CDT组3.8±0.70天 vs 单纯CDT组6.2±1.40天(P=.024);术后血管造影次数:PCDT+CDT组1.2±0.30次 vs 单纯CDT组2.4±0.80次(P=.042);III级静脉通畅(溶栓>95%):PCDT+CDT组68.6% vs 单纯CDT组54.5%(P=.047)。
关键数值与推荐
- PTS(Villalta评分≥5分或静脉性溃疡)发生率:PCDT+CDT组27.7% vs 单纯CDT组47.0%(P=.037)。
- 12个月中重度PTS发生比例:PCDT+CDT组4.5% vs 单纯CDT组15.7%(P=.024)。
- 24个月中重度PTS发生比例:PCDT+CDT组11.4% vs 单纯CDT组35.3%(P=.016)。
临床怎么用
- 原文结论认为,在症状持续时间≤7天的髂股深静脉血栓亚组中,PCDT+CDT的短期和长期结局均支持其优于单纯CDT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to compare the outcomes of pharmacomechanical thrombolysis and thrombectomy (PCDT) plus catheter-directed thrombolysis (CDT) vs CDT alone for the treatment of acute iliofemoral deep vein thrombosis (DVT) and summarize the clinical experience, safety outcomes, and short- and long-term efficacy. METHODS: We performed a 4-year retrospective, case-control study. A total of 95 consecutive patients with acute symptomatic iliofemoral deep vein thrombosis (DVT) with a symptom duration of ≤7 days involving the iliac and/or common femoral veins underwent endovascular interventions. The patients were divided into two groups according to their clinical indications: PCDT plus CDT vs CDT alone. Statistical analyses were used to compare the clinical characteristics and outcomes between the two groups. Additionally, the patients were followed up for 3 to 36 months after treatment, and the proportions of post-thrombotic syndrome (PTS) and moderate to severe PTS were analyzed using the Kaplan-Meier survival method. RESULTS: A total of 95 consecutive patients were analyzed in this retrospective study, of whom, 51 underwent CDT alone and 44 underwent PCDT plus CDT. Between the two groups, in terms of immediate-term efficacy and safety, significant differences were found in the catheter retention time (60.64 ± 12.04 hours vs 19.42 ± 4.04 hours; P < .001), dosages of urokinase required (5.82 ± 0.81 million units vs 1.80 ± 0.64 million units; P < .001), the detumescence rate at 24 hours postoperatively (48.46% ± 8.62% vs 76.79% ± 7.98%; P = .026), the descent velocity of D-dimer per day (2266.28 ± 1358.26 μg/L/D vs 3842.34 ± 2048.02 μg/L/D; P = .018), total hospitalization stay (6.2 ± 1.40 days vs 3.8 ± 0.70 days; P = .024), number of postoperative angiograms (2.4 ± 0.80 vs 1.2 ± 0.30; P = .042), and grade III venous patency (>95% lysis: 54.5% vs 68.6%; P = .047). Furthermore, during the follow-up period, significant differences were found in the incidence of PTS (Villalta scale ≥5 or a venous ulcer: 47.0% vs 27.7%; P = .037), and the incidence proportion of moderate to severe PTS at 12 months (15.7% vs 4.5%; P = .024) and 24 months (35.3% vs 11.4%; P = .016). CONCLUSIONS: Compared with CDT alone, in the iliofemoral DVT subgroup with a symptom duration of ≤7 days, PCDT plus CDT could significantly relieve early leg symptoms, shorten the hospitalization stay, reduce bleeding complications, promote long-term venous patency, and decrease the occurrence of PTS and the incidence proportion of moderate to severe PTS. Thus, the short- and long-term outcomes both support the superiority of PCDT plus CDT vs CDT in this subgroup.
引用
- Kang T, Lu YL, Han S, et al. Comparative outcomes of catheter-directed thrombolysis versus AngioJet pharmacomechanical catheter-directed thrombolysis for treatment of acute iliofemoral deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37625507. doi:10.1016/j.jvsv.2023.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。